Current Research Studies
A two-stage double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation
EPIK-L1
What is the goal of the study?
To demonstrate the efficacy and safety and assess pharmacokinetics of alpelisib in participants with lymphatic malformations associated with a PIK3CA mutation.
Who can participate in the study?
Please contact the study team listed below to learn more.